Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York City that focuses on brain health—particularly new treatments for major psychiatric conditions. The company recently adopted the Definium name as part of a broader effort to align its brand with a science-led mission in modern psychiatry.
At its core, Definium is an R&D-driven drug developer aiming to create next-generation therapeutics designed to address underlying drivers of psychiatric and neurological disorders, with the goal of producing durable, meaningful improvement rather than short-lived symptom relief.
A defining element of Definium’s approach is its focus on psychedelic-based medicine—emphasizing scientific rigor and clinical evidence while exploring how compounds historically associated with psychedelics might be translated into scalable, regulated therapies. The company describes its work as “retracing LSD to its origins” to unlock clinical potential in a way that fits modern medical standards.
Definium’s late-stage development efforts are centered on anxiety and depression, with DT120 (an orally disintegrating tablet, or ODT) positioned as the lead program for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company has highlighted multiple Phase 3 studies in these indications and notes that DT120 ODT has received FDA Breakthrough Therapy Designation for GAD.
Beyond its lead program, Definium also maintains earlier-stage pipeline work, including clinical development of DT402 in adults with autism spectrum disorder (ASD). Overall, the company’s day-to-day operations revolve around running clinical trials, generating evidence for regulators and clinicians, and building the operational readiness needed to bring a psychiatric therapy to market if it earns approval.